---
title: "Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295683903.md"
description: "Cantor Fitzgerald analyst Kristen Kluska reiterated a Buy rating on Eupraxia Pharmaceuticals (EPRX) with a $19.00 price target. Kluska, a 5-star analyst in the Healthcare sector, maintains this stance despite the broader market consensus showing a Strong Buy with an average price target of $17.01."
datetime: "2026-08-12T15:05:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295683903.md)
  - [en](https://longbridge.com/en/news/295683903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295683903.md)
generator: "portal-rs"
---

# Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

Cantor Fitzgerald analyst Kristen Kluska reiterated a Buy rating on Eupraxia Pharmaceuticals yesterday and set a price target of $19.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Kluska is a 5-star analyst with an average return of 23.8% and a 48.57% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Celldex, Codexis, and Eupraxia Pharmaceuticals.

Currently, the analyst consensus on Eupraxia Pharmaceuticals is a Strong Buy with an average price target of $17.01.

### Related Stocks

- [EPRX.US](https://longbridge.com/en/quote/EPRX.US.md)
- [CLDX.US](https://longbridge.com/en/quote/CLDX.US.md)
- [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md)

## Related News & Research

- [Eupraxia says EP-104GI keeps 64% of EoE patients in remission at 52 weeks in RESOLVE trial data](https://longbridge.com/en/news/300568655.md)
- [HC Wainwright & Co. reiterates Buy rating on Eupraxia Pharmaceuticals, $11 price target](https://longbridge.com/en/news/300671439.md)
- [Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)](https://longbridge.com/en/news/293226746.md)
- [Netflix CEO Says Company’s Growth Not Good Enough: ‘Working on Making that Move Faster’](https://longbridge.com/en/news/300705564.md)
- [Google Stock Gets $420 Price Target from BNP Paribas – Here's Why](https://longbridge.com/en/news/300731266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**